TY - JOUR
T1 - Radiation therapy for metastatic spinal cord compression in patients with hepatocellular carcinoma
AU - Rades, Dirk
AU - Dahlke, Markus
AU - Janssen, Stefan
AU - Gebauer, Niklas
AU - Bartscht, Tobias
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Aim: This is the first study to investigate patients with metastatic spinal cord compression (MSCC) from hepatocellular carcinoma (HCC). Patients and Methods: Eight patients were analyzed with regard to survival and motor dysfunction. Results: Out of seven factors (age, affected vertebrae, ambulatory status, bone lesions, other distant metastases, time developing motor dysfunction, performance score) ambulatory status (p=0.005) and distant metastases (p=0.032) had a significant influence on survival. Both factors were used as a predictive tool (points: not ambulatory 0, ambulatory 1, distant metastases 0, no distant metastases 1). Total scores were 0, 1 or 2 points. Threemonth survival rates were 0%, 67% and 100%, six-month survival rates 0%, 0% and 100%. Progression of motor dysfunction was prevented in 63% of patients; time developing motor deficits showed a trend (p=0.08). Conclusion: Many patients with MSCC from HCC have a short survival, which can be predicted with a new tool. Radiation therapy can stop progression of motor dysfunction.
AB - Aim: This is the first study to investigate patients with metastatic spinal cord compression (MSCC) from hepatocellular carcinoma (HCC). Patients and Methods: Eight patients were analyzed with regard to survival and motor dysfunction. Results: Out of seven factors (age, affected vertebrae, ambulatory status, bone lesions, other distant metastases, time developing motor dysfunction, performance score) ambulatory status (p=0.005) and distant metastases (p=0.032) had a significant influence on survival. Both factors were used as a predictive tool (points: not ambulatory 0, ambulatory 1, distant metastases 0, no distant metastases 1). Total scores were 0, 1 or 2 points. Threemonth survival rates were 0%, 67% and 100%, six-month survival rates 0%, 0% and 100%. Progression of motor dysfunction was prevented in 63% of patients; time developing motor deficits showed a trend (p=0.08). Conclusion: Many patients with MSCC from HCC have a short survival, which can be predicted with a new tool. Radiation therapy can stop progression of motor dysfunction.
UR - https://www.scopus.com/pages/publications/84958150487
M3 - Journal articles
C2 - 26546531
AN - SCOPUS:84958150487
SN - 0258-851X
VL - 29
SP - 749
EP - 752
JO - In Vivo
JF - In Vivo
IS - 6
ER -